Nelson Advisors Partner Lloyd Price has been invited to Judge the PitchFest Awards at ReWired 2026. This is the third time Lloyd has judged the prestigious awards, highlighting the pedigree of UK Digital Health and MedTech companies. Unlike standard "demo days," PitchFest is specifically designed to break down the barriers between start-ups and the NHS. The judges are not just venture capitalists but also Chief Information Officers (CIOs) and Chief Clinical Information Office

Nelson Advisors invited to Chair the 'Health Data Under Attack: Emerging Vulnerabilities in Healthcare' Panel at Health Tech Forward 2025 Nelson Advisors Partner Lloyd Price Chaired the 'Health Data Under Attack: Emerging Vulnerabilities in Healthcare panel' at Health Tech Forward 2025 in Barcelona this week. The  panel focused around 5 main questions debated by the guests Laura, Alberto and Naoufal. 1) Laura Busquet Raich, Head of Data Protection and ComplianceConsorci de Sa

Nelson Advisors Partner Lloyd Price was invited to Chair the discussions at the IESE Business School Healthcare Club event on the 3rd December in Barcelona. Lloyd was joined on the panel by Javier Matacàs, Investment Director at Careventures and ⁠Ilan Misano, CEO of X-Applied and former Head of the StartUp Growth Lab - Google Israel's startup accelerator.

Nelson Advisors thought leadership has been referenced in the Forbes article '5 High-Growth Business Models Set To Thrive In The Coming Decade' outlining five business models that are primed for success in the coming years.

The intersection between defense innovation and medical technology (MedTech) represents a fundamental structural shift, moving beyond simple technological spillovers to establish a mutually reinforcing economic and R&D ecosystem. Military Research and Development (R&D) functions as a highly accelerated, high-stakes validation engine, forcing the creation of exceptionally robust, autonomous, and efficient medical capabilities required for assured care in austere and contested

The major stories in the world of European MedTech this week are dominated by regulatory activity under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), a significant European Commission "Call for Evidence" for future reforms, and fresh funding for companies focused on connected and remote monitoring devices.

The MedTech mergers and acquisitions (M&A) landscape is undergoing a profound and irreversible transformation. The traditional playbook, which long emphasised incremental product improvements and narrowly focused acquisitions, has become largely obsolete. A new era has emerged, defined by the strategic convergence of medical technology, data intelligence, and consumer-centric care models.